A mother's antibodies that can help shield her infant from getting measles may not last long, according to new research.
A mother's antibodies that can help shield her in- fant from getting measles may not last very long, increasing her baby's risk for measles well before the 12-month vaccination, new research published online May 18 in BMJ shows.
Antibodies extended immunity for a median of 0.97 months in infants of vaccinated women, according to researchers at the University of Antwerp, Belgium. Babies born to women with naturally acquired immunity had more protection-a median of 3.78 months-until necessary levels of the maternal measles antibodies disappeared.
By age 6 months, researchers noted that more than 99% and 95% of infants, respectively, did not have any more maternal antibodies against measles.
At the 1-, 6-, 9-, and 12-month follow-up visits, infants of vaccinated women had lower antibody concentrations. Immunity remained steady in 29% of infants born to vaccinated women and 60% of infants born to women with naturally acquired immunity by 3 months of age. No infant in the study had adequate maternal antibodies at age 9 or 12 months.
Infant RSV hospitalization rates 28%, 43% lower this season vs pre-COVID seasons
May 9th 2025"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.